Detalles de la búsqueda
1.
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol;
2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38696053
2.
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.
Int J Clin Oncol;
2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38578596
3.
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38649648
4.
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.
Int J Clin Oncol;
29(5): 545-550, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38517658
5.
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
29(5): 559-563, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38538963
6.
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
29(5): 551-558, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38526621
7.
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
29(4): 355-362, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38353907
8.
Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale.
Breast Cancer;
31(2): 234-242, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38079066
9.
Simultaneous Tumor Shrinkage and Bronchial Perforation Induced by Nivolumab plus Cabozantinib Combination Therapy in a Patient with Collecting Duct Carcinoma.
Chemotherapy;
69(1): 45-48, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-37820606
10.
Complete response of metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus cabozantinib.
IJU Case Rep;
6(6): 419-423, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37928303
11.
One-year changes in activities of daily living and social life in elderly patients undergoing home-based rehabilitation within 1 year of stroke onset.
J Phys Ther Sci;
35(10): 689-695, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37791002
12.
The prevalence of lynch syndrome (DNA mismatch repair protein deficiency) in patients with primary localized prostate cancer using immunohistochemistry screening.
Hered Cancer Clin Pract;
21(1): 20, 2023 Oct 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37828628
13.
Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis.
Int J Clin Oncol;
28(12): 1651-1658, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37658926
14.
BRAF Mutation Heterogeneity Detected Using Circulating Tumor DNA Sequencing in Synchronous Colon Cancer: A Case Report.
Cancer Diagn Progn;
3(5): 605-608, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37671312
15.
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
N Engl J Med;
389(5): 477, 2023 Aug 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37530835
16.
A Case Report of Aggressive Fumarate Hydrase-deficient Renal Cell Carcinoma With Loss of HLA Antigens.
Cancer Diagn Progn;
3(4): 522-527, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37405222
17.
Nationwide Database Analysis of Risk Factors Associated with Decreased Activities of Daily Living in Patients with Alzheimer's Disease.
J Alzheimers Dis;
94(4): 1465-1475, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37393499
18.
Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan.
J Med Econ;
26(1): 1009-1018, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37505931
19.
Cabozantinib-induced serum creatine kinase elevation and rhabdomyolysis: a retrospective case series.
Cancer Chemother Pharmacol;
92(3): 235-240, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37380798
20.
Bell's palsy during rechallenge of immune checkpoint inhibitor.
IJU Case Rep;
6(2): 144-146, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36875003